Polypoidal Choroidal Vasculopathy
Conditions
Interventions
Sponsors
Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Written informed consent 2) wAMD on FA, ICGA and OCT 3) PCV on fundus photography and ICGA 4) Treatment-naïve PCV 5) BCVA>0.05
Exclusion criteria
Exclusion criteria: 1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2) Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3) Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 4) Active intraocular inflammation 5) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 6) pregnant women and nursing mothers 7) Patient who the doctor in charge judges are ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of improved/maintained visual acuity at month 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of BCVA (best-collected visual acuity), central macular thickness and subretinal fluid on OCT (optical coherence tomography), disease area on fluorescent angiography (FA), regression of polyp on indocyanine green angiography (ICGA) | — |
Countries
Japan
Contacts
Public ContactYuji Oshima
Graduate School of Medical Sciences, Kyushu University Department of Ophthalmology
Outcome results
None listed